These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8620667)

  • 1. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
    Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interactions between zileuton and prednisone.
    Awni WM; Cavanaugh JH; Tzeng TB; Witt G; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():105-11. PubMed ID: 8620666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of zileuton on theophylline pharmacokinetics.
    Granneman GR; Braeckman RA; Locke CS; Cavanaugh JH; Dubé LM; Awni WM
    Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.
    Depré M; Van Hecken A; Verbesselt R; De Lepeleire I; Schwartz J; Porras A; Larson P; Lin C; De Schepper PJ
    Int J Clin Pharmacol Res; 1998; 18(2):53-61. PubMed ID: 9675622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.
    Sahota T; Sanderson I; Danhof M; Della Pasqua O
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):209-19. PubMed ID: 24667227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
    Awni WM; Hussein Z; Cavanaugh JH; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():92-7. PubMed ID: 8620677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of food on the pharmacokinetics of zileuton.
    Awni WM; Cavanaugh JH; Witt G; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():62-6. PubMed ID: 8620672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
    Machinist JM; Kukulka MJ; Bopp BA
    Clin Pharmacokinet; 1995; 29 Suppl 2():34-41. PubMed ID: 8620669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
    J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
    Samara E; Cavanaugh JH; Mukherjee D; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():84-91. PubMed ID: 8620675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa.
    Treiber G; Wex T; Link A; Vieth M; Laufer S; Malfertheiner P
    Aliment Pharmacol Ther; 2006 Jan; 23(1):155-67. PubMed ID: 16393293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
    Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
    Awni WM; Cavanaugh JH; Leese P; Kasier J; Cao G; Locke CS; Dube LM
    Eur J Clin Pharmacol; 1997; 52(1):49-54. PubMed ID: 9143867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
    Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH
    Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
    Awni WM; Braeckman RA; Granneman GR; Witt G; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():22-33. PubMed ID: 8620668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
    Wong SL; Awni WM; Cavanaugh JH; el-Shourbagy T; Locke CS; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of zileuton in healthy young and elderly volunteers.
    Braeckman RA; Granneman GR; Locke CS; Machinist JM; Cavannaugh JH; Awni WM
    Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.